Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Total Liabilities (2022 - 2025)

Oramed Pharmaceuticals' Total Liabilities history spans 4 years, with the latest figure at $31.1 million for Q4 2025.

  • For Q4 2025, Total Liabilities changed N/A year-over-year to $31.1 million; the TTM value through Dec 2025 reached $31.1 million, changed N/A, while the annual FY2025 figure was $31.1 million, N/A changed from the prior year.
  • Total Liabilities reached $31.1 million in Q4 2025 per ORMP's latest filing, up from $18.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $82.7 million in Q3 2023 to a low of $5.7 million in Q2 2023.
  • Average Total Liabilities over 4 years is $21.1 million, with a median of $10.0 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: surged 632.18% in 2023, then tumbled 88.44% in 2024.
  • A 4-year view of Total Liabilities shows it stood at $10.5 million in 2022, then skyrocketed by 449.86% to $57.7 million in 2023, then crashed by 83.42% to $9.6 million in 2024, then surged by 225.56% to $31.1 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Total Liabilities are $31.1 million (Q4 2025), $18.2 million (Q3 2025), and $8.1 million (Q2 2025).